| " Benign" monoclonal IgE gammopathy. H Ludwig British Medical Journal (Clinical research ed.) 282 (6265), 739, 1981 | | 1981 |
| " Benign" monoclonal IgE gammopathy. H Ludwig, W Vormittag Br Med J 281 (6239), 539-540, 1980 | 25 | 1980 |
| “Laying on of hands” improves well-being in patients with advanced cancer G Pohl, H Seemann, N Zojer, C Ochsner, C Luhan, M Schemper, ... Supportive care in cancer 15, 143-151, 2007 | 33 | 2007 |
| 100 Overall survival data of patients with MDS, AML and CMML from the Austrian Azacitidine Registry of 184 consecutive patients L Pleyer, R Stauder, J Thaler, H Ludwig, M Pfeilstöcker, S Steinkirchner, ... Leukemia Research, S38, 2011 | 3 | 2011 |
| 101 Age-and comorbidity-specific evaluation of azacitidine treatment, response and overall survival in 184 patients in the Austrian Azacitidine Registry L Pleyer, R Stauder, J Thaler, H Ludwig, M Pfeilstoecker, S Steinkirchner, ... Leukemia Research, S38-S39, 2011 | 4 | 2011 |
| 11.5 Multiples Myelom und Morbus Waldenström H Ludwig Praktische Rheumatologie, 522, 2001 | | 2001 |
| 1104 POSTER Patient-level integrated analysis of data from 6 randomized, double-blind, placebo-controlled trials of darbepoetin alfa (DA) in patients (pts) with chemotherapy … H Ludwig, J Crawford, A Österborg, A Fleishman, T Lillie, T Süto, J Glaspy EJC Supplements 4 (5), 142-143, 2007 | 4 | 2007 |
| 1120 POSTER Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated … J Glaspy, A Österborg, H Ludwig, A Fleishman, T Lillie, T Süto, J Crawford EJC Supplements 4 (5), 147-148, 2007 | | 2007 |
| 12 Remission Maintenance H Ludwig, N Zojer Biology and Management of Multiple Myeloma, 223, 2004 | | 2004 |
| 15 INVITED Open questions about biosimilars–pharmacovigilance, substitution, labelling, naming and economy H Mellstedt, H Ludwig, D Niederwieser EJC Supplements 4 (5), 7-8, 2007 | | 2007 |
| 15 Pathogenesis and Treatment H Ludwig, A Osterborg Biology and Management of Multiple Myeloma, 303, 2004 | | 2004 |
| 15 Pathogenesis and Treatment of Anemia H Ludwig Biology and Management of Multiple Myeloma: staging and prognostic factors …, 2004 | | 2004 |
| 1596 Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia (CIN/FN) prophylaxis with biosimilar filgrastim and development of an outcomes risk … M Aapro, H Ludwig, C Bokemeyer, P Gascón, M Boccadoro, M Turner, ... European Journal of Cancer 3 (51), S236, 2015 | | 2015 |
| 16 INVITED Follow-on erythropoietins–Pros and cons H Ludwig EJC Supplements 4 (5), 8, 2007 | | 2007 |
| 17 INVITED G-CSF biosimilars–approval process, substitution and extrapolation D Niederwiesser, H Ludwig, H Mellstedt EJC Supplements 4 (5), 8, 2007 | | 2007 |
| 1985 EURAGE Monoclonal gammapathies-Clinical significance and basic mechanisms J Radl, W Hijmans, B van Camp, RG Lynch Monoclonal Gammapathies: Clinical Significance and Basic Mechanisms …, 1985 | | 1985 |
| 2016 IMWG 建议: 骨髓瘤相关肾损害的诊断和管理 MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... | | |
| 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde P Musto, M Engelhardt, J Caers, M Kaiser, N Van de Donk, E Terpos, ... haematologica 106 (11), 2799, 2021 | 30 | 2021 |
| 5-Fluorouracil and Folinic Acid with or without Alpha-2c Interferon in the Treatment of Metastatic Colorectal Cancer: Preliminary Results of a Multicenter Prospective … R Moser, H Hausmaninger, H Ludwig, M Fridrik, H Schmidt, B Mlineritsch, ... Oncology Research and Treatment 18 (2), 131-135, 1995 | 3 | 1995 |
| 5-FLUOROURACIL, ADRIAMYCIN AND HIGH-DOSE METHOTREXATE IN CHEMOTHERAPY IN MULTIPLE-MYELOMA-A PHASE-3 STUDY OF THE EUROPEAN-MYELOMA-STUDY-GROUP-FOR-INTERFERON W SCHEITHAUER, H LUDWIG, C ZIELINSKI, J FUNOVICS, ... ONKOLOGIE 10 (5), 280-281, 1987 | | 1987 |
